Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-marketing surveillance of albumin-bound paclitaxel for breast cancer.

Trial Profile

Post-marketing surveillance of albumin-bound paclitaxel for breast cancer.

Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2013

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 21 Feb 2013 New trial record
    • 14 Feb 2013 Results from this post-marketing surveillance have been reported in a Taiho Pharmaceutical media release. These findings were sufficient to support the lifting of a previous condition for approval of Abraxane set forth by the Japanese regulatory body.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top